Eisai Co., Ltd. and Biogen Inc. announced that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (su...
Telix Pharmaceuticals Limited announced completion of patient enrollment in the Phase 3 BiPASS™ study of its commercial PSMA-PET imaging agent...
Eisai Co., Ltd. and Biogen Inc., announced that Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of...
- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population - - More than 90% of p...
Roche announced new two-year data from the Phase IIIb/IV SALWEEN study of Vabysmo® (faricimab), presented at the 19th Asia-Pacific Vitreo-retina Soci...
Roche announced that it has received FDA approval for expanded use of its PATHWAY® HER2 (4B5) and VENTANA® HER2 Dual ISH DNA Probe Coc...
Revolution Medicines, Inc., a global commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patie...
Perceptra Co., Ltd., a Thai startup developing artificial intelligence technology for medical image analysis, has officially announced its entry into ...
Eisai Co., Ltd. and Biogen Inc., announced that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK®) is now available in th...
Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, announced that t...
Ipsen announced it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor navt...
Alvotech , a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced a str...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced to...
Lundbeck announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593, the company's lead oral orexin 2 rece...
© 2026 Biopharma Boardroom. All Rights Reserved.
